Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis

被引：0
|
作者：
Rojas, Silvia M.
Diez-Campelo, Maria
Luno, Elisa
Bernal, Teresa
Cabrero, Monica
Pedro, Carme
Calabuig, Marisa
Nomdedeu, Benet
Cedena, Teresa
Arrizabalaga, Beatriz
Garcia, Marta
Cervero, Carlos
Collado, Rosa
Azaceta, Gemma
Ardanaz, MarAa Teresa
Munoz, Juan A.
Xicoy, Blanca
Requena, Maria Jose
Bargay, Joan
Arilla, Maria Jesus
Amigo, Luz
Merchan, Brayan
Simiele, Adriana
Brunet, Salut
Gonzalez, Bernardo
Ramos, Fernando
Sole, Francesc
Consuelo, Del CaA'izo
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1542.1542
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1542
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
    Pierre Fenaux
    Aristoteles Giagounidis
    Dominik Selleslag
    Odile Beyne-Rauzy
    Moshe Mittelman
    Petra Muus
    Stephen D. Nimer
    Eva Hellström-Lindberg
    Bayard L. Powell
    Agnes Guerci-Bresler
    Mikkael A. Sekeres
    H. Joachim Deeg
    Consuelo del Cañizo
    Peter L. Greenberg
    Jamile M. Shammo
    Barry Skikne
    Xujie Yu
    Alan F. List
    Journal of Hematology & Oncology, 10
  • [22] Disease progression in del(5q) MDS patients treated with lenalidomide: Analysis of risk factors and long term outcome in 45 patients
    Giagounidis, A.
    Haase, S.
    Lohrbacher, V.
    Schuran, B.
    Heinsch, M.
    Aul, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 85 - 85
  • [23] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    A Kuendgen
    M Lauseker
    A F List
    P Fenaux
    A A Giagounidis
    N A Brandenburg
    J Backstrom
    A Glasmacher
    J Hasford
    U Germing
    Leukemia, 2013, 27 : 1072 - 1079
  • [24] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    Kuendgen, A.
    Lauseker, M.
    List, A. F.
    Fenaux, P.
    Giagounidis, A. A.
    Brandenburg, N. A.
    Backstrom, J.
    Glasmacher, A.
    Hasford, J.
    Germing, U.
    LEUKEMIA, 2013, 27 (05) : 1072 - 1079
  • [25] THE PROGNOSTIC SIGNIFICANCE OF TP53 MUTATIONS IN MDS PATIENTS WITH DEL(5Q)
    Belickova, M.
    Vesela, J.
    Jonasova, A.
    Planetova, B.
    Valka, J.
    Mikulenkova, D.
    Zemanova, Z.
    Brezinova, J.
    Michalova, K.
    Cermak, J.
    LEUKEMIA RESEARCH, 2015, 39 : S22 - S23
  • [26] Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
    Rufer, Axel
    Angermann, Hubert
    Benz, Rudolf
    Bonadies, Nicolas
    Calderoni, Antonello
    Cantoni, Nathan
    Efthymiou, Anna
    Escher, Robert
    Favre, Genevieve
    Friess, Dorothea
    Gschwend, Andreas
    Himmelmann, Andreas
    Holbro, Andreas
    Keller, Peter
    Kouroupi, Eirini
    Lehmann, Thomas
    Pedarnig, Nikolaus
    Rigamonti, Veronique
    Samii, Kaveh
    Schmidt, Adrian
    Schafer, Hans-Peter
    Sperb, Roland
    Stussi, Georg
    Winkler, Annette
    Zenhausern, Reinhard
    Goede, Jeroen S.
    HEMASPHERE, 2022, 6 (07):
  • [27] MDS-005 STUDY: EFFECT OF BASELINE ENDOGENOUS EPO ON RBC TRANSFUSION INDEPENDENCE (RBC-TI) IN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MDS WITHOUT DEL(5Q)
    Santini, V.
    Li, J. S.
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S59 - S59
  • [28] Telomere dynamics in patients with del (5q) MDS before and under treatment with lenalidomide
    Beier, Fabian
    Kharabi Masouleh, Behzad
    Buesche, Guntram
    Ventura Ferreira, Monica S.
    Schneider, Rebekka K.
    Ziegler, Patrick
    Wilop, Stefan
    Vankann, Lucia
    Gattermann, Norbert
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Goetze, Katharina S.
    Nolte, Florian
    Hofmann, Wolf-Karsten
    Haase, Detlef
    Kreipe, Hans
    Panse, Jens
    Blasco, Maria A.
    Germing, Ulrich
    Bruemmendorf, Tim H.
    LEUKEMIA RESEARCH, 2015, 39 (11) : 1292 - 1298
  • [29] Phase 3 Study of Lenalidomide vs Placebo in Non-Transfusion Dependent Low Risk del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 17 - 18
  • [30] Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases
    Smoljanovic, Inga Mandac
    Taylor, Adele
    Fenaux, Pierre
    Guerci-Bresler, Agnes
    Itzykson, Raphael
    Symeonidis, Argiris
    Kotsianidis, Ioannis
    Mittelman, Moshe
    Sanz, Guillermo
    Culligan, Dominic J.
    Cermak, Jaroslav
    Stauder, Reinhard
    Hellstrom-Lindberg, Eva
    Malcovati, Luca
    Langemeijer, Saskia M. C.
    Germing, Ulrich
    Madry, Krzysztof
    Oster, Howard S.
    Smith, Alexandra
    van Marrewijk, Corine
    de Witte, Theo M.
    Bowen, David
    BLOOD, 2022, 140 : 9802 - 9803
12345